摘要
目的探讨善胃系列方分型论治慢性萎缩性胃炎(CAG)癌前病变的临床疗效。方法选取2013年7月—2014年12月在中国人民武装警察部队后勤学院附属医院首长保健科和消化科门诊接受治疗的CAG癌前病变患者90例。根据CAG癌前病变中医证候诊断标准分为血瘀热毒型30例、热毒伤阴型30例、气阴两虚型30例,按血瘀热毒型、热毒伤阴型、气阴两虚型分别给予善胃Ⅰ、Ⅱ、Ⅲ号中药全成分配方颗粒进行辨证治疗6个月。于治疗前和治疗后观察患者症状的变化情况,并进行综合疗效、中医证候疗效、幽门螺杆菌(Hp)转阴率、胃镜疗效和病理疗效评价。结果血瘀热毒型、热毒伤阴型、气阴两虚型患者综合疗效的总有效率分别为90.0%(27/30)、93.3%(28/30)、70.0%(21/30)。血瘀热毒型、热毒伤阴型和气阴两虚型患者治疗后中医证候疗效得分与治疗前比较,差异均有统计学意义(P<0.05)。治疗后血瘀热毒型、热毒伤阴型和气阴两虚型患者的Hp转阴率分别为89.3%(25/28)、68.2%(15/22)、46.2%(6/13)。血瘀热毒型、热毒伤阴型、气阴两虚型患者胃镜疗效的总有效率分别为73.3%(22/30)、80.0%(24/30)、63.3%(19/30)。血瘀热毒型、热毒伤阴型和气阴两虚型患者治疗后病理疗效得分与治疗前比较,差异均有统计学意义(P<0.05)。结论善胃系列方可明显改善CAG癌前病变患者的临床症状、中医证候疗效、胃镜疗效和病理疗效,提高Hp转阴率。
Objective To explore the clinical efficacy of Shanwei formula series for precancerous lesion of chronic atrophic gastritis （CAG） . Methods From July 2013 to December 2014, we enrolled 90 patients with precancerous lesion of CAG who received treatment in the Head Department of Healthcare and Gastroenterology Department of the Affiliated Hospital of Medical College of Chinese People＇s Armed Police Force. According to TCM syndrome diagnostic criteria of precancerous lesion of CAG, the patients were divided into three syndromes ： noxious heat blood stasis syndrome （ n = 30）, syndrome of yin - damage by heat toxin （ n = 30 ）, syndrome of deficiency of both vital energy and yin （ n = 30 ） . Patients of the three syndromes were given TCM composition formula particles of Shanwei formula series I , Ⅱand Ⅲ respectively. Before and after treatment, the changes of symptoms of the patients were observed, and comparisons were made in comprehensive efficacy, TCM syndrome efficacy, Hp eradication rate, gastroscope curative effect and pathological effect. Results The overall effective rates of the comprehensive treatment on patients of the three syndromes, namely noxious heat blood stasis syndrome, syndrome of yin - damage by heat toxin, and syndrome of deficiency of both vital energy and yin were 90. 0% （27/30）, 93.3% （28/30） and 70. 0% （21/30） respectively. Patients of the three syndromes were significantly different in the scores of TCM syndrome efficacy between before and after treatment （P 〈 0. 05） . After treatment, the Hp eradication rates of patients of the three syndromes were 89. 3% （25/28）, 68.2% （15/22） and 46. 2% （6/13） respectively, and the overall effective rates of gastroscope were 73.3% （22/30）, 80.0% （24/30） and 63.3% （19/30） respectively. Patients of the three syndromes were significantly different in the scores of pathologic effect between before and after treatment （ P 〈 0. 05 ） . Conclusion Shanwei formula series can effectively improve the clinical syndrome of patients with precancerous lesion of CAG, TCM syndrome efficacy, gastroscope efficacy, pathological efficacy and Hp eradication rate.
出处
《中国全科医学》
CAS
CSCD
北大核心
2016年第19期2348-2351,共4页
Chinese General Practice
基金
国家自然科学基金资助项目(81273745)
关键词
胃炎
萎缩性
癌前病变
善胃系列方
Gastritis, atrophic
Precancerous lesions
Shanwei formula series
